Characteristics of the entire melanoma cohort and according to primary tumor type
| Entire cohort (n=249) | Cutaneous (n=183) | Mucosal (n=28) | Unknown primary (n=20) | Acral (n=18) | P value | |
| Genomic subtype | ||||||
| BRAF V600E/K | 86 (35%) | 78 (43%) | 0 (0%) | 5 (25%) | 3 (17%) | 0.0106 |
| NRAS | 69 (28%) | 46 (25%) | 7 (25%) | 10 (50%) | 6 (33%) | |
| BRAF/NRAS WT | 94 (38%) | 59 (32%) | 21 (75%) | 5 (25%) | 9 (50%) | |
| Age | ||||||
| <60 | 122 (49%) | 90 (49%) | 16 (57%) | 6 (30%) | 10 (56%) | 0.2703 |
| ≥60 | 127 (51%) | 93 (51%) | 12 (43%) | 14 (70%) | 8 (44%) | |
| Gender | ||||||
| Male | 145 (58%) | 115 (63%) | 12 (43%) | 11 (55%) | 7 (39%) | 0.2377 |
| Female | 104 (42%) | 68 (37%) | 16 (57%) | 9 (45%) | 11 (61%) | |
| No of metastatic sites | ||||||
| >3 | 184 (74%) | 134 (54%) | 21 (75%) | 17 (75%) | 12 (67%) | 0.6133 |
| ≤3 | 65 (26%) | 49 (46%) | 7 (25%) | 3 (25%) | 6 (33%) | |
| M-stage | ||||||
| M0/M1a/M1b | 93 (37%) | 78 (43%) | 4 (14%) | 3 (15%) | 8 (44%) | 0.0039 |
| M1c/M1d | 156 (63%) | 105 (57%) | 24 (86%) | 17 (85%) | 10 (56%) | |
| LDH | ||||||
| <1.5 x ULN | 183 (74%) | 146 (80%) | 14 (50%) | 14 (70%) | 9 (50%) | 0.0050 |
| ≥1.5 x ULN | 65 (26%) | 36 (20%) | 14 (50%) | 6 (30%) | 9 (50%) | |
| NLR | ||||||
| <5 | 188 (76%) | 139 (76%) | 18 (64%) | 15 (75%) | 16 (89%) | 0.2933 |
| ≥5 | 60 (24%) | 43 (24%) | 10 (36%) | 5 (25%) | 2 (11%) | |
| Anti-PD1 regimen | ||||||
| Anti-PD1 | 172 (69%) | 136 (74%) | 15 (54%) | 10 (50%) | 11 (61%) | 0.0234 |
| Anti-PD1+anti-CTLA4 | 77 (31%) | 47 (26%) | 13 (46%) | 10 (50%) | 7 (39%) | |
| Line of therapy | ||||||
| First | 135 (54%) | 94 (51%) | 18 (64%) | 14 (70%) | 9 (50%) | 0.2776 |
| Second or later | 114 (46%) | 89 (49%) | 10 (36%) | 6 (30%) | 9 (50%) |
WT, wild type.